Creating Long-term Sustainable Value
Our Business Model
Our diversified business model enables us to respond to the many opportunities and challenges we face while delivering value for our patients, employees, shareholders, and wider communities. We operate in a competitive, highly-regulated industry.
We ensure our investors have an in-depth understanding of our operations, financial performance, growth drivers, and ESG efforts.
Measuring Progress
We deliver our strategy through our three strategic priorities and measure our performance with key performance indicators (KPIs), including the Core revenue which measures our ability to maximize value from our current product portfolio across our global markets and generate income from new launches. The NOVAK core revenue in the year 2021 increased by 9% reflecting good performance from all three business segments, supported by recent solid product launches. The Core operating profit measures our ability to grow revenue and maintain quality while delivering efficiencies and ensuring cost control. In 2021 the increases in core operating profit were driven by good revenue growth across our all market segments and strong growth in Generics profitability.
Building Trust through Quality in Everything We do
Upholding the Universal Declaration of Human Rights and improving human rights oversight across our value chain.
We are committed to upholding the highest ethical standards in the conduct of our global business operations, which is grounded in our culture of progress and belonging, and powered by our three core values: innovative, caring, and collaborative.
We also strictly comply with GMP and GMP-related standards to ensure quality at our sites. Ensuring that all existing and new suppliers have their details assessed by the Risk Rate platform to indicate compliance with modern slavery protocols.
Pioneering access solutions for our innovative therapies
Generic medicines play an important role in helping alleviate pressures on global healthcare budgets. As NOVAK's purpose is to provide quality medicine across the globe, we are committed to increasing patient's access to more affordable healthcare. In 2021, we launched various products across our markets and our continuous investment in R&D and manufacturing capabilities enables us to meet patients’ growing demand.
Environmental, Social, and Governance (ESG)
ESG is central to the NOVAK strategy and is critical to delivering on our purpose to Advance medicines to improve people’s lives. Coupled with our inspired, curious, and unbossed culture, we believe ESG efforts on our most material topics will help drive our overall performance as a company and deliver long-term value for our stakeholders. Looking ahead, we are renewing our focus on our ESG material topics, redoubling our efforts on improving access to medicines, and accelerating our journey toward a zero-carbon future.
Whether you're a distributor, career seeker, medical professional, or an investor, you can contact us through the below global NOVAK email:
(Switzerland I Global)
Monday - Friday
8:30 a.m. - 5:00 p.m. GMT+1
For product-related inquiries and medical information about our products, please contact the NOVAK office in your country.
© 2022 by NOVAK Pharmaceuticals.
Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.